11 results
PrimaryTo evaluate the pharmacokinetics of two different tablet formulations of BCI-952 compared to the over-encapsulated BCI-952 product components.SecondaryTo evaluate the safety and tolerability following the administration of two different…
In this study we want to investigate whether the submission of zoledronic acid to neoadjuvant chemotherapy benefits the pathological complete response, and thus favors a better clinical outcome in patients with large ressectable or locally advanced…
Whether disrupting reconsolidation by a noradrenergic β-blocker provides long-term relief of PTSD symptoms in traumatized healthcare workers.
Whether disrupting reconsolidation by a noradrenergic beta-blocker provides long-term relief from nicotine-addiction.
The purpose of the study is to compare LA-EP2006 and Neulasta®US and Neulasta®EU with respect to how quickly and to what extent the compounds are absorbed and eliminated from the body after injection under the skin of the abdomen (this is called…
The purpose of the study is to investigate the ability of MYL-1401H to evoke an immune response (immunogenicity) as compared to Neulasta® US. In addition, the effect of MYL-1401H on blood cells as compared to Neulasta® US will be investigated. The…
To determine the mechanism of action of propranolol in the prophylactic treatment of migraine.
The purpose of the study is research. The study investigates to what extent ANF Rho is tolerated in comparison to Neulasta® (representing standard of care treatment) and placebo. A placebo is the same formulation as the study medication without the…
Here, we aim to test whether disrupting reconsolidation by a noradrenergic *-blocker provides long-term relief of panic symptoms in burned-out employees.
1. To investigate the acute effect of ADRB2 activation, via intravenous administration of salbutamol (250 µg), on 18F-FDG uptake by BAT.2. To assess the acute effect of ADRB2 activation via intravenous administration of salbutamol (250 µg) on…
Whether disrupting reconsolidation by a noradrenergic *-blocker provides long-term relief of PTSD symptoms in combat veterans.